EVALOF EFFICACY OF ONCE/DAY PROTEASE INHBTR& ONCE/DAY NONNUCLEOSIDE REVERSE

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 A5175是一项IV期随机、开放标签、三臂抗病毒疗效试验，旨在评估三种抗逆转录病毒(ARV)方案治疗新型艾滋病毒感染患者的疗效：一种方案包含两种核苷逆转录酶抑制剂(NRTI)+一种HIV-1蛋白酶抑制剂(PI)；以及两种方案，每种方案包含两种NRTI+一种非核苷逆转录酶抑制剂(NNRTI)。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. A5175 is a phase IV, randomized, open-label, three-arm antiviral efficacy trial designed to evaluate three antiretroviral (ARV) regimens for treatment na¿ve HIV-infected participants: one regimen containing two nucleoside reverse transcriptase inhibitors (NRTIs) + an HIV-1 protease inhibitor (PI) regimen, and two regimens each containing two NRTIs + a non-nucleoside reverse transcriptase inhibitor (NNRTI).